Filter Results:
(777)
Show Results For
- All HBS Web
(937)
- People (2)
- News (70)
- Research (777)
- Events (1)
- Multimedia (2)
- Faculty Publications (668)
Show Results For
- All HBS Web
(937)
- People (2)
- News (70)
- Research (777)
- Events (1)
- Multimedia (2)
- Faculty Publications (668)
Sort by
- May 1998
- Teaching Note
Merck-Medco: Vertical Integration in the Pharmaceutical Industry TN
By: V. Kasturi Rangan and Marie Bell
Teaching Note for (9-598-091). View Details
Keywords: Pharmaceutical Industry
- December 2005
- Article
Understanding Firm, Physician and Consumer Choice Behavior in the Pharmaceutical Industry
This paper argues that the pharmaceutical industry represents an exciting opportunity to carry out academic research. The nature of the industry allows researchers to answer new questions, develop new methodologies for answering these questions as well as to apply... View Details
Manchanda, Puneet, Dick R. Wittink, Andrew Ching, Paris Cleanthous, Min Ding, Xiaojing J. Dong, Peter S. H. Leeflang, Sanjog Misra, Natalie Mizik, Sridhar Narayanan, Thomas J. Steenburgh, Jaap E. Wieringa, Marta Wosinska, and Ying Xie. "Understanding Firm, Physician and Consumer Choice Behavior in the Pharmaceutical Industry." Marketing Letters 16, nos. 3/4 (December 2005): 293 – 308.
- 2001
- Chapter
Publicly Funded Science and the Productivity of the Pharmaceutical Industry
By: Rebecca Henderson and Ian Cockburn
U.S. taxpayers funded $14.8 billion of health related research last year, four times the amount that was spent in 1970 in real terms. In this paper we evaluate the impact of these huge expenditures on the technological performance of the pharmaceutical industry. While... View Details
Keywords: Public Sector; Science-Based Business; Research and Development; Sovereign Finance; Pharmaceutical Industry
Henderson, Rebecca, and Ian Cockburn. "Publicly Funded Science and the Productivity of the Pharmaceutical Industry." In Innovation Policy and the Economy, Volume 1, edited by Adam B. Jaffe, Josh Lerner, and Scott Stern, 1–34. MIT Press, 2001.
- March 2023
- Teaching Note
Hikma Pharmaceuticals Governance Journey
By: Suraj Srinivasan and Jonah Goldberg
Teaching Note for HBS Case No. 318108. The case opens with Said Darwazah, chairman and CEO of Hikma Pharmaceuticals, the multinational generics company, anticipating the company’s 2017 AGM and reflecting on changes made over the previous year to address concerns... View Details
Keywords: Jordan; Emerging Market; Private Sector; For-profit Firms; Boards Of Directors; Pharmaceuticals; Remuneration; Shareholder Engagement; Corporate Governance; Governing and Advisory Boards; Business and Shareholder Relations; Executive Compensation; Business Growth and Maturation; Pharmaceutical Industry; Jordan
- Working Paper
Rebates in the Pharmaceutical Industry: Evidence from Medicines Sold in Retail Pharmacies in the U.S.
By: Pragya Kakani, Michael Chernew and Amitabh Chandra
Rising list prices are often used to illustrate the burden of prescription drug spending, but payers routinely negotiate rebates from manufacturers that generate differences between list and net prices. List prices are easily available and affect patient cost-sharing,... View Details
Keywords: Pharmaceuticals; Rebates; Health Care and Treatment; Markets; Price; Analysis; Pharmaceutical Industry
Kakani, Pragya, Michael Chernew, and Amitabh Chandra. "Rebates in the Pharmaceutical Industry: Evidence from Medicines Sold in Retail Pharmacies in the U.S." NBER Working Paper Series, No. 26846, March 2020.
- August 2001
- Case
Pharmaceutical Industry and the AIDS Crisis in Developing Countries, The
Explores the controversy over the pricing of AIDS drugs in poor countries. This issue has received wide publicity due to two events: 1) a court case in South Africa that seeks to force drug companies to license their patents and 2) the announcement by the Indian... View Details
Keywords: Competition; Developing Countries and Economies; Business and Government Relations; Pharmaceutical Industry; South Africa; India
Kennedy, Robert E. "Pharmaceutical Industry and the AIDS Crisis in Developing Countries, The." Harvard Business School Case 702-010, August 2001.
- July 1998 (Revised October 1998)
- Case
Jan Eriksson at Novartis Indonesia: Turmoil in the Indonesian Pharmaceutical Industry
By: Carin-Isabel Knoop and Anthony St. George
Jan Eriksson is the country manager of the Indonesian joint venture of Basel-based Novartis (Novartis Indonesia), the world's largest pharmaceutical company, formed by the 1996 merger between Sandoz and Ciba-Geigy. The case describes the actions he has taken since... View Details
Keywords: Joint Ventures; Mergers and Acquisitions; Crisis Management; Management Teams; Financial Crisis; Pharmaceutical Industry; Indonesia
Knoop, Carin-Isabel, and Anthony St. George. "Jan Eriksson at Novartis Indonesia: Turmoil in the Indonesian Pharmaceutical Industry." Harvard Business School Case 899-040, July 1998. (Revised October 1998.)
- September 2017
- Teaching Note
Dr. William Carson— Intrapreneurial Innovation in the Pharmaceutical Industry
By: Steven Rogers and Alyssa Haywoode
Teaching Note for HBS No. 318-005. View Details
- November 1997 (Revised November 2010)
- Case
Hikma Pharmaceuticals (A)
By: John A. Quelch
The president of a Jordanian pharmaceutical company is contemplating how to further penetrate the U.S. market, either through its own manufacturing and sales efforts, or as a supplier to a third party. View Details
Keywords: Entrepreneurship; Globalized Markets and Industries; Emerging Markets; Expansion; Pharmaceutical Industry; Jordan; United States
Quelch, John A., and Robin Root. "Hikma Pharmaceuticals (A)." Harvard Business School Case 598-019, November 1997. (Revised November 2010.)
- June 2002 (Revised November 2005)
- Case
Life, Death, and Property Rights: The Pharmaceutical Industry Faces AIDS in Africa
By: Debora L. Spar
In the final years of the 20th century, the world was hit by a plague of epidemic proportions--AIDS, a life-threatening disease that remained stubbornly immune to any cure or vaccine. In the developed nations of the West, AIDS was slowly brought under control through a... View Details
Keywords: Patents; Health Pandemics; Corporate Social Responsibility and Impact; Pharmaceutical Industry; Africa
Spar, Debora L., and Nick Bartlett. "Life, Death, and Property Rights: The Pharmaceutical Industry Faces AIDS in Africa." Harvard Business School Case 702-049, June 2002. (Revised November 2005.)
- November 2010
- Supplement
Hikma Pharmaceuticals (B)
By: John A. Quelch
By 2009, Hikma Pharmaceuticals operated 13 manufacturing plants in 8 countries of which 5 were approved by the U.S. Food and Drug Administration. Hikma tracked its sales revenues over the period to show where the largest contributors were from. View Details
Quelch, John A. "Hikma Pharmaceuticals (B)." Harvard Business School Supplement 511-075, November 2010.
- 22 Apr 2009
- Working Paper Summaries
Where is the Pharmacy to the World? International Regulatory Variation and Pharmaceutical Industry Location
- 2008
- Chapter
Where is the Pharmacy to the World? Pharmaceutical Industry Location and International Regulatory Variation
By: Arthur A. Daemmrich
A consumer-oriented model for drug development and use has attracted attention in recent years as an alternative to the much-maligned approach of mass-marketing blockbuster drugs. In a parallel development, patients and disease-based organizations have assumed greater... View Details
Keywords: Geographic Location; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Demand and Consumers; Pharmaceutical Industry; European Union; Germany; United States
Daemmrich, Arthur A. "Where is the Pharmacy to the World? Pharmaceutical Industry Location and International Regulatory Variation." Chap. 16 in Ways of Regulating: Therapeutic Agents between Plants, Shops, and Consulting Rooms. Vol. 363, edited by Jean Paul Gaudillière and Volker Hess, 271–290. Berlin, Germany: Max-Planck-Institut für Wissenschaftsgeschichte, 2008.
- November 2007 (Revised October 2009)
- Case
Ligand Pharmaceuticals Incorporated
In an activist role, the hedge fund Third Point LLC has three board seats and an ownership stake of 9.5% in Ligand Pharmaceuticals, Inc., a specialty pharmaceutical company. Third Point believed that Ligand had a strong drug portfolio and pipeline but that it was... View Details
Keywords: Mergers and Acquisitions; Private Equity; Investment Activism; Investment Funds; Governing and Advisory Boards; Bids and Bidding; Ownership Stake; Pharmaceutical Industry; United States
El-Hage, Nabil N., and Michael Gorzynski. "Ligand Pharmaceuticals Incorporated." Harvard Business School Case 208-019, November 2007. (Revised October 2009.)
- October 1976 (Revised June 1980)
- Case
Dana Pharmaceutical
By: Thomas R. Piper
Keywords: Pharmaceutical Industry
Piper, Thomas R. "Dana Pharmaceutical." Harvard Business School Case 277-073, October 1976. (Revised June 1980.)
- 2009
- Working Paper
Where Is the Pharmacy to the World? International Regulatory Variation and Pharmaceutical Industry Location
By: Arthur Daemmrich
A consumer-oriented model for drug development and use has attracted attention in recent years as an alternative to the much-maligned approach of mass-marketing blockbuster drugs. In a parallel development, patients and disease-based organizations have assumed greater... View Details
Keywords: Governing Rules, Regulations, and Reforms; Health Disorders; Health Testing and Trials; Power and Influence; Competitive Strategy; Pharmaceutical Industry; European Union; Germany; United States
Daemmrich, Arthur. "Where Is the Pharmacy to the World? International Regulatory Variation and Pharmaceutical Industry Location." Harvard Business School Working Paper, No. 09-118, April 2009.
- 05 Jul 2006
- Working Paper Summaries
Do Managers’ Heuristics Affect R&D Performance Volatility? A Simulation Informed by the Pharmaceutical Industry
- December 1992 (Revised September 1996)
- Case
ImmuLogic Pharmaceutical Corporation (Abridged)
By: Josh Lerner
ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The rationales for and problems of high-technology start-ups are explored. The challenges posed by "windows" for public offerings are... View Details
Keywords: Decisions; Initial Public Offering; Entrepreneurship; Going Public; Business Startups; Biotechnology Industry; Biotechnology Industry; United States
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (Abridged)." Harvard Business School Case 293-087, December 1992. (Revised September 1996.)